RT Journal Article
SR Electronic
T1 Molecular Imaging of <em>HER2</em>-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic <sup>111</sup>In- or <sup>68</sup>Ga-Labeled Affibody Molecules
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 892
OP 897
DO 10.2967/jnumed.109.073239
VO 51
IS 6
A1 Richard P. Baum
A1 Vikas Prasad
A1 Dirk Müller
A1 Christiane Schuchardt
A1 Anna Orlova
A1 Anders Wennborg
A1 Vladimir Tolmachev
A1 Joachim Feldwisch
YR 2010
UL http://jnm.snmjournals.org/content/51/6/892.abstract
AB The clinical utility of a human epidermal growth factor receptor 2 (HER2)–targeting Affibody molecule for detection and characterization of HER2-positive lesions was investigated in patients with recurrent metastatic breast cancer. Methods: Three patients received 111In- or 68Ga-labeled DOTA0-ZHER2:342-pep2 (ABY-002). γ-Camera, SPECT, or PET/CT images were compared with earlier 18F-FDG PET/CT results. Results: Administration of radiolabeled ABY-002 was well tolerated. Blood kinetics of radiolabeled ABY-002 showed a first half-life of 4–14 min, second half-life of 1–4 h, and third half-life of 12–18 h. Radiolabeled ABY-002 detected 9 of 11 18F-FDG–positive metastases as early as 2–3 h after injection. Conclusion: Molecular imaging using 111In- or 68Ga-labeled ABY-002 has the potential to localize metastatic lesions in vivo, adds qualitative information not available today by conventional imaging techniques, and may allow the HER2 status to be determined for metastases not amenable to biopsy. To our knowledge, this is the first report on clinical imaging data obtained with a non–immunoglobulin-based scaffold protein.